(1)(8)F-NaF PET/CT and (1)(1)C-Choline PET/CT for the initial detection of metastatic disease in prostate cancer: overview and potential utilization.

  • Koo P
  • David Crawford E
  • 6


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


With the rapid increase in new therapies to treat advanced prostate cancer, improved diagnosis tools are necessary to help refine patient management throughout the entire disease course. Many radiopharmaceuticals, most of which are imaged using positron emission tomography/computed tomography (PET/CT), are in development; two of these newer radiopharmaceuticals are (1)(8)F-sodium fluoride (NaF) and radiolabeled choline. Compared with traditional imaging, use (1)(8)F-NaF has been shown to improve sensitivity and specificity, and radiolabeled choline has been shown to detect recurrent and metastatic disease earlier. We briefly review these two imaging technologies and provide potential utilization strategies based on available data.

Author-supplied keywords

  • Bone Neoplasms
  • Carbon Radioisotopes
  • Choline
  • Fluorine Radioisotopes
  • Humans
  • Male
  • Multimodal Imaging
  • Neoplasm Staging
  • Positron-Emission Tomography
  • Prognosis
  • Prostatic Neoplasms
  • Radiopharmaceuticals
  • Sodium Fluoride
  • Tomography, X-Ray Computed
  • diagnostic use
  • pathology
  • radionuclide imaging
  • secondary
  • utilization

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Phillip J Koo

  • E David Crawford

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free